Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
CLDX
#3995
Celldex Therapeutics, Inc
30.090
0
+0.40%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+0.40%
Changement Mensuel
+14.80%
Evolution sur 6 mois
+10.46%
Changement Annuel
+10.46%
Clôture Précédente
29.970
0
Open
30.000
0
Bid
Ask
Low
30.000
0
High
30.090
0
Volume
102
Marchés
Actions des Marchés US
Soins de Santé
CLDX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
39.61 M
46.74 M
47.21 M
55.9 M
66.38 M
66.57 M
—
Valuation ratios
Enterprise value
650.21 M
1.77 B
2.02 B
2.22 B
1.65 B
1.78 B
5.98 B
Price to earnings ratio
—
-23.56
-18.08
-13.84
-10.31
-6.96
-28.1
Price to sales ratio
—
0.36
0.86
0.28
0.23
1.17
2.21
Price to cash flow ratio
—
0.03
0.02
0.02
0.01
0.01
0.03
Price to book ratio
—
0
0.01
0
0
0
0
Enterprise value to EBITDA ratio
-30.59
-108.09
-91.6
-104.31
-57.79
-45.5
—
Profitability ratios
Return on assets %
0.25
0.16
0.24
0.2
0.13
0.44
0.41
Return on equity %
0.29
0.17
0.26
0.21
0.14
0.49
0.44
Return on invested capital %
483.12
711.84
937.82
1 040.56
1 165.13
2 329.78
—
Gross margin %
97.3
97.85
95.76
95.64
97.15
87.06
400
Operating margin %
854.06
1 531.78
4 889.01
2 245.27
2 778.89
18.6 K
-7.27 M
EBITDA margin %
-286.52
-351.43
-935.09
-309.79
-406.48
-2 530.81
—
Net margin %
805.88
1 516.04
3 616.25
1 331.85
1 462.49
16.75 K
-6.62 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
13.93
24.86
17.07
13.87
18.91
10.49
64.83
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.01
0.02
0.01
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
1 420.57
2 211.65
2 214.7
2 450.5
3 175.83
3 176.63
EBIT per share
—
-452.83
-531.82
-502.2
-492.46
-639.56
—
EBITDA per share
—
-381.27
-470.06
-440.11
-443.12
-588.68
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
9 522.98
6 503.84
8 743.17
11.26 K
7 807.25
36.22 K
Net current asset value per share
—
9 583.37
6 775.57
8 910.26
11.6 K
8 049.5
37.37 K
Tangible book value per share
—
9 150.59
6 377.2
8 296.99
11.18 K
7 527.25
35.77 K
Working capital per share
—
9 197.83
6 378.67
8 267.83
10.99 K
7 281.82
34.92 K
Book value per share
—
9 784.84
6 957.09
8 858.2
11.6 K
7 936.6
37.41 K
Nouvelles
Celldex présente des données de phase 2 pour le traitement de l’urticaire chronique
Celldex presents phase 2 data for chronic urticaria treatment
Celldex Therapeutics Stock Earns 88 RS Rating
Le BPA de Celldex Therapeutics a manqué les attentes de 0,21$, le CA en dessous des prévisions
Celldex Therapeutics earnings missed by $0.21, revenue fell short of estimates
L’action Celldex Therapeutics atteint un sommet de 52 semaines à 30,66 $
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Stifel réitère sa recommandation sur Celldex Therapeutics suite aux progrès des essais
Stifel reiterates Celldex Therapeutics stock rating on trial progress
Celldex termine le recrutement de Phase 3 pour le traitement de l’UCE en avance
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule
Notation de l’action Celldex réitérée comme Surpondérer par Cantor Fitzgerald